Phase II Study of Intrathecal I-3F8 [monoclonal-antibody-3F8-I-131] in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2018
At a glance
- Drugs Monoclonal antibody 3F8 I-131 (Primary)
- Indications Astrocytoma; CNS cancer; Ependymoma; Glioma; Malignant melanoma; Medulloblastoma; Meningeal carcinomatosis; Neuroblastoma; Retinoblastoma; Rhabdoid tumour; Sarcoma; Small cell lung cancer
- Focus Therapeutic Use
- 26 Oct 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 26 Oct 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
- 12 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.